Core Insights - Hoth Therapeutics, Inc. has announced significant advancements in its proprietary antisense oligonucleotide (ASO) cancer drug candidate, HT-KIT, focusing on allergic and inflammatory diseases [1][4] Intellectual Property Developments - The company has filed amended claims with the U.S. Patent and Trademark Office for its lead ASO technology targeting MS4A6A and FcεRIβ, enhancing intellectual property protection for HT-KIT [2] - These refined claims position HT-KIT as a novel therapeutic platform with potential applications in treating conditions such as anaphylaxis, mastocytosis, and allergic asthma [2] Preclinical Studies - Hoth has initiated a GLP-compliant 4-week intravenous toxicity study in C57BL/6 mice, which includes a 14-day recovery period [3] - This preclinical study aims to evaluate the safety profile of HT-KIT and will involve multiple dose groups, detailed pathology assessments, and pharmacokinetic profiling [3] Future Development Plans - The company is committed to advancing HT-KIT toward clinical evaluation and is conducting additional preclinical studies to validate its efficacy and safety [4] - Plans are in place to initiate regulatory discussions for first-in-human trials as part of the development process [4]

Core Insights - Hoth Therapeutics, Inc. announced breakthrough preclinical findings for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST), demonstrating significant tumor burden reduction and disruption of KIT signaling pathways [2][3][4] Group 1: Key Findings from Preclinical Study - HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, with lower doses leading to substantial cell death at 72 hours [6][7] - HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, confirmed by reductions in cell count and decreased fluorescence intensity in proliferation assays [6][7] - In a humanized xenograft model, HT-KIT treatment (12.5 mg/kg IV every three days) led to significant tumor growth reduction, with statistically significant differences observed by day 8 [6][7] - Excised tumors from HT-KIT-treated mice were smaller and lighter than those in the control group, reinforcing tumor volume measurements [6][7] Group 2: Treatment Mechanism and Potential - HT-KIT effectively reduced KIT receptor expression within 24 hours, with effects sustained for 72 hours [7] - By targeting KIT mutations, HT-KIT has shown remarkable efficacy in preclinical models, indicating its potential as a transformative treatment option for GIST [3][4][5] Group 3: Next Steps in Development - Hoth Therapeutics is advancing HT-KIT toward clinical evaluation, conducting additional preclinical studies to validate its efficacy and safety profile [5] - Plans are in place to initiate regulatory discussions for first-in-human trials [5]

Core Viewpoint - Hoth Therapeutics is advancing HT-001, a therapeutic candidate aimed at alleviating dermatological side effects in cancer patients undergoing EGFR inhibitor treatments, and plans to submit an Expanded Access application to provide access to this treatment outside traditional clinical trials [1][2]. Company Overview - Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve patient quality of life, emphasizing a patient-centric approach in its research and development efforts [3]. Expanded Access Program - The Expanded Access Program (EAP) is designed to provide investigational treatments to patients with serious or life-threatening conditions who lack comparable treatment options, allowing Hoth Therapeutics to offer HT-001 to eligible patients while collecting data on its safety and efficacy [2]. Leadership Commitment - Robb Knie, CEO of Hoth Therapeutics, highlighted the submission of the Expanded Access application as a significant step in the company's commitment to addressing critical unmet medical needs and improving the quality of life for cancer patients [2].

Core Insights - Hoth Therapeutics, Inc. has announced promising findings for its novel therapeutic candidate HT-001, a topical neurokinin 1 receptor (NK1R) antagonist, aimed at treating Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions (EGFRi PPEs) [3][6] Group 1: Clinical Findings - A recent case study highlighted the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer, who experienced full symptom and lesion resolution after one week of treatment, with no recurrence in the following three weeks [2][5] - The patient developed pruritic, burning red papules, a known side effect of EGFR inhibitors, which were effectively treated with HT-001 [2][5] Group 2: Upcoming Presentation - Data regarding HT-001 will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, scheduled for March 7-11, 2025, emphasizing its potential as a breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities [1][4] Group 3: Company Strategy and Research - Hoth Therapeutics is conducting a Phase 2A clinical trial to evaluate the efficacy and safety of HT-001 in a broader patient population, assessing its effectiveness across varying severities of EGFRi PPEs and other dermatologic manifestations induced by EGFR inhibitors [7] - The company aims to address the significant unmet need for long-term, well-tolerated treatment options for cancer patients experiencing debilitating skin reactions [6]

Core Insights - Hoth Therapeutics has announced preclinical findings indicating that Glial Cell Line-Derived Neurotrophic Factor (GDNF) may serve as a groundbreaking treatment for obesity, demonstrating significant reductions in fat accumulation and improvements in metabolism and insulin sensitivity [2][4][6] Group 1: Study Findings - GDNF significantly reduces fat accumulation and enhances metabolism in GDNF-transgenic models, even under high-fat diet conditions [2][4] - The study shows that GDNF increases basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake [6][7] - GDNF inhibits fat cell formation by suppressing key genes involved in fat storage and promoting fat oxidation pathways [6][7] - Enhanced glucose tolerance and lower serum leptin levels in GDNF-tg mice indicate improved metabolic health [6][7] - GDNF prevents hepatic steatosis, a common obesity-related complication, thereby reducing the risk of fatty liver disease [6][7] Group 2: Implications for Obesity Treatment - The findings suggest a paradigm shift in obesity treatment, moving away from traditional methods focused on appetite suppression to a mechanism that enhances the body's natural ability to burn fat [3][4] - GDNF-based therapies could provide a new approach to obesity management by activating natural metabolic processes, representing a significant advancement over current anti-obesity drugs [5][6] Group 3: Future Development Plans - Hoth Therapeutics is exploring various pathways for clinical translation of GDNF-based therapies, including recombinant protein delivery, gene therapy, and small-molecule mimetics [8] - The company plans to initiate further preclinical and clinical development efforts to bring this potential therapy closer to patients [8]

Core Insights - Hoth Therapeutics, Inc. has announced a collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT, marking a significant step in its preclinical development [1][3] - The study focuses on the development and optimization of staining methods for c-Kit markers, which are critical to the therapeutic mechanism of HT-KIT [2] - HT-KIT is a preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers, representing a potential advancement in precision oncology therapies [3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative and impactful treatments aimed at improving patient quality of life [4] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [4]

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The Company received written notification from Nasdaq on January 23, 2025, stating that because the Company's com ...

IP will be used to pursue further indications for HT-001 Cancer TherapeuticNEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline.These newly secured patents reflect Hoth's commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on ...

Company Overview - Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments aimed at improving patient quality of life [2] - The company engages in early-stage pharmaceutical research and development, advancing drugs from bench to pre-clinical and clinical testing [2] - Hoth Therapeutics employs a patient-centric approach, collaborating with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [2] Recent Developments - Robb Knie, the CEO of Hoth Therapeutics, is scheduled to attend the Sequire Investor Summit, indicating the company's engagement with investors and the broader financial community [1]

Financial Position - The company has no plans for a public or private offering at this time [1][3] - The company maintains a strong financial position with over $10 million in cash and no debt [1][3] - This fiscal strength allows the company to execute strategic initiatives and advance its pipeline without immediate need for additional financing [3] Clinical Trials - Enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants [2][4] - HT-001 is the company's lead therapeutic candidate designed to treat rash and skin disorders associated with cancer therapy [4] - Activating all trial sites for HT-001 marks a significant milestone in the development of this promising therapy [5] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative, patient-focused treatments [2][6] - The company is dedicated to improving patient quality of life through groundbreaking treatments [6] - Hoth collaborates with scientists, clinicians, and key opinion leaders to investigate therapeutics with potential for breakthroughs and diversified treatment options [6] Leadership Statement - The CEO emphasized the company's focus on creating long-term value and advancing clinical programs [4] - The company remains committed to addressing unmet needs for patients undergoing cancer treatment [5] - Hoth is dedicated to transparency and will provide updates as material developments occur [5]